research Self-assembled polymeric nanocarriers for the targeted delivery of retinoic acid to the hair follicle
The new micelle formulation delivers acne treatment more effectively and safely than current gels.
Search
for
Sort by
Research
630-660 / 1000+ results 
research Alopecia areata: Time for position statement to include new systemic therapeutic advances
New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.
research LB1159 First-in-human clinical trial evaluating AI-09, a novel long-lasting ready-to-use liquid injectable neuromodulator for the treatment of glabellar lines
AI-09 is safe, effective, and reduces wrinkles for up to 6 months.
research 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure
Baricitinib is a safe and effective treatment for severe alopecia areata.
research S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
research The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
research Complete remission of alopecia areata under treatment of chronic hand eczema with alitretinoin
Alitretinoin may help treat alopecia areata.
research 219 Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid
Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.
research Non-scarring Alopecia in Pemphigus Foliaceus
Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.
research JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
research Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
research Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata
Leflunomide is more likely to help treat alopecia areata than cause it.
research 1348 Involvement of mast cells and CB1 in the pathogenesis of IgA vasculitis
Mast cells and the CB1 receptor may be key in causing IgA vasculitis.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research Local infusion of infliximab for the treatment of acute joint inflammation
Co-trimoxazole may help treat autoimmune diseases.
research INDUCTION OF PSORIASIFORM CHANGES IN GUINEA PIG SKIN BY PROPRANOLOL
Propranolol combined with injections caused skin changes in guinea pigs but didn't fully mimic psoriasis.
research Drug news and therapeutic news
JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
research Leflunomide
Leflunomide is effective for rheumatoid arthritis but has significant side effects.
research Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
research Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
research Denosumab-induced alopecia areata with lichenoid eruption
Denosumab, a bone loss treatment, may cause hair loss and skin reactions due to immune system effects.
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Correction to ‘Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study’
research Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials
Extended-release divalproex is better tolerated and more effective for seizures and psychiatric symptoms than delayed-release divalproex, but doesn't reduce hair loss.
research Association of psoriasis and psoriatic arthritis with human leukocyte antigen and killer cell immunoglobulin–like receptor gene frequency: A multiethnic population study
Certain immune system genes are linked to a higher risk of psoriasis and psoriatic arthritis, while others may offer protection.
research Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know
Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
research Pseudallescheria boydii infection associated with IgG4-related disease
research Case report of novel combination of anthralin and calcipotriene leading to trichologic response in alopecia areata
A new mix of anthralin and calcipotriene might help treat severe hair loss.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.
research Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy
Sintilimab treatment caused hair loss but led to complete tumor remission.